Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05543252 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 2
- Development phase
- 428
- Enrollment target
NCT05543252: Clinical Trial Phase 2 study, sponsored by UCB Biopharma SRL.
NCT05543252 is a Phase 2 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 428 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (222% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05543252, a Phase 2 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 428 participants
- Enrollment target
Study Summary
The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
Primary Outcome
Change from PD0053 Baseline (screening) in mean striatum specific binding ratio (SBR) was assessed by DaT-SPECT using 123I-Ioflupane. Whole striatum was calculated as average of SBR data values for the four following "small" regions: left caudate, right caudate, left putamen, and right putamen. SBR was calculated for each region with the occipital cortex as a reference region. SBR = Average Small region minus Average Occipital region divided by Average Occipital region. Lower SBR indicated worse
Interventions
- DRUG Minzasolmin (UCB0599)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2025-03-25 |
| Phase | Phase 2 |
Why NCT05543252 stopped before completion
NCT05543252 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (222% higher).
The record links to 0 conditions, and to 1 intervention - of which Minzasolmin (UCB0599) is the first listed.
NCT05543252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05543252 about?
NCT05543252 is a clinical study titled "An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease". The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
What is the current status of trial NCT05543252?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 428 participants. The study started on 2022-08-29. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT05543252?
The interventions under investigation include: Minzasolmin (UCB0599) (DRUG).
Who is sponsoring clinical trial NCT05543252?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05543252's enrollment target sits among peer trials
428 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI